Table 1.

KATHERINE baseline demographics.

TrastuzumabAdo-trastuzumab emtansine
(N = 743)(N = 743)
Age (years), median (range)49 (23–80)49 (24–79)
Female, n (%)740 (99.6%)741 (99.7%)
Race, n (%)
 American Indian or Alaskan native50 (6.7%)36 (4.8%)
 Asian64 (8.6%)65 (8.7%)
 Black19 (2.6%)21 (2.8%)
 White531 (71.5%)551 (74.2%)
 Other or unknown79 (10.6%)70 (9.4%)
Region, n (%)
 North America164 (22.1%)170 (22.9%)
 Western Europe403 (54.2%)403 (54.2%)
 Rest of World176 (23.7%)170 (22.9%)
Hormone receptor (positive), n (%)210 (28.3%)213 (28.7%)
Preoperative HER2 therapy, n (%)
 Trastuzumab596 (80.2%)600 (80.8%)
 Trastuzumab + additional HER2 therapy147 (19.8%)143 (19.2%)
Preoperative pertuzumab (yes), n (%)139 (18.7%)133 (17.9%)
Prior anthracycline use (yes), n (%)564 (75.9%)579 (77.9%)
Menopausal status (post), n (%)330 (44.4%)344 (46.3%)
ECOG status (0), n (%)613 (82.5%)597 (80.3%)
  • Abbreviation: ECOG, Eastern Cooperative Oncology Group.